Nyxoah Highlights Positive Early Findings from Neurostimulator Trial for Sleep Apnea
The company has completed all 115 implants in the DREAM trial and expects full 12-month data in the first quarter of next year.
The company has completed all 115 implants in the DREAM trial and expects full 12-month data in the first quarter of next year.
The clinical and regulatory milestones bring Nyxoah closer to offering its Genio neurostimulator solution to OSA patients in the US, according to the company.
Inspire Medical Systems Inc has made equity investments in two private companies, EnsoData Inc in Wisconsin and Ognomy Inc in New York.
Genio 2.1’s upgrades are entirely related to the external components of the Genio system, as the implantable stimulator remains unchanged.
Read MoreOne key factor driving Inspire’s growth achieved during Q1 was the performance of the company’s Advisor Care Program.
Read MoreChildren with Down syndrome and sleep apnea are more likely to experience aggressive behavior, brain fogging, and a loss of nearly 10 points in IQ compared to those without.
Read MoreNeurostimulators don’t have decades of patient data like CPAP, but Inspire and remedē’s 1- and 5-year outcome studies show sustained benefits.
Read MoreInspire achieved significant therapy utilization milestones in Q4 including the 20,000th patient being implanted with the device.
Read MoreInspire Medical announced Tuesday that its 2021 revenue would be between $233 million and $233.4 million, a robust increase of about 102% over the previous year.
Read MoreA second chance for many patients, devices like Inspire and remede also facilitate new avenues for marketing.
Read More“It was easy to find 20 minutes during the day to use it and the results have paid off. My husband now sleeps better without my snoring, and so do I.”
Read MoreModerated by Sairam Parthasarathy, MD, FAASM, the topic is particularly timely due to shortages of CPAP devices caused in part by the Philips CPAP/bilevel recall.
Read MoreInspire’s core objective with this report is to allow its customers to make informed decisions related to the best treatment options.
Read MoreCMS will review the panel’s recommendations, and the final rules will be published later in 2021.
Read MoreA flow chart from Sleep 360 Sleep Diagnostic Center illustrates the OSA patient journey from referral to customized therapy.
Read MoreProceeds of the financing will be directed towards commercialization of eXciteOSA in core target markets, continued development of proprietary digital patient and physician interface platforms, the generation of additional clinical data to reinforce the therapeutic efficacy of eXciteOSA, and progressing reimbursement.
Read MoreThis randomized controlled trial will take place at approximately 20 sites across the United States and will enroll a maximum of 150 adult patients with moderate to severe OSA who do not achieve results from a traditional CPAP machine or have declined its use.
Read MoreVagal-evoked potentials were largest during a specific sleep stage called nonREM sleep, during which large, slow waves dominate the electrical activity of the brain.
Read More